Search
for
Sort by
Research 31–60 of 778
- JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia
- Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
- Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
- Current and future pharmacotherapy for alopecia areata
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
- Unexpected Effect of Baricitinib Use: Observation of a Case of Hypertrichosis
- Possible Involvement of Skin‐Resident Memory T Cells in Refractory Chronic Alopecia Areata
- 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo
- Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia
- Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
- Hair follicle stem cells and the collapse of self-tolerance in alopecia: the interplay of barrier function, the microbiome, and immunity
- JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
- 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Advances in the mechanism and new therapies of alopecia areata
- Citrullination at the Inflammatory Skin Barrier
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about?
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
- Emerging role of baricitinib in dermatology practice: All we need to know!
- 0975 Single-cell transcriptomic profiling reveals distinct immunopathogenic programs in alopecia totalis/universalis compared to patchy alopecia areata
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Alopecia areata treatment with baricitinib: different relapse phenotypes
- Baricitinib in pediatric chronic immune thrombocytopenia and associated autoimmune conditions: a case report